Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The move to Research Triangle Park follows Immunovia’s model development study and completion of the discovery phase for its next-generation test in November 2023. Following these developments, the company will focus […]
About half of the 26 employees were made redundant prior to the bankruptcy and the other half have had their employment agreements terminated following the bankruptcy. As things stand, most of the members of the leadership team are available for a short period of time to ensure compliance with applicable regulatory requirements and to assist […]
The company has announced the successful closure of an oversubscribed bridge financing round. Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis […]
Recently, the annual Entrepreneur’s Gala took place at Uppsala Castle to honor companies that showed exceptional performance during the past year and the Entrepreneur of the Year award was awarded to Ulrika Hammarström, CEO and Founder of Scandinavian CRO (SCRO). This prize is awarded by jury to an entrepreneur who has performed above and beyond […]
Researchers at Chalmers University of Technology in Sweden have carried out one of the largest studies to date using AI (artificial intelligence)-assisted image analysis of lymphoma. “An AI-based computer system for interpreting medical images also contributes to increased equality in healthcare by giving patients access to the same expertise and being able to have their […]
The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed, states the company. “Triple-negative breast cancer is a very aggressive disease with poor prognosis. The […]
Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]
In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were […]
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.